학술논문
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Document Type
Article
Author
Source
In: Diabetes Technology and Therapeutics . (Diabetes Technology and Therapeutics, September 2019, 21(9):471-477)
Subject
Language
English
ISSN
15578593
15209156
15209156